BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8943866)

  • 1. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.
    Ben-Yehuda D; Krichevsky S; Caspi O; Rund D; Polliack A; Abeliovich D; Zelig O; Yahalom V; Paltiel O; Or R; Peretz T; Ben-Neriah S; Yehuda O; Rachmilewitz EA
    Blood; 1996 Dec; 88(11):4296-303. PubMed ID: 8943866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p53 gene in pediatric therapy-related leukemia and myelodysplasia.
    Felix CA; Hosler MR; Provisor D; Salhany K; Sexsmith EA; Slater DJ; Cheung NK; Winick NJ; Strauss EA; Heyn R; Lange BJ; Malkin D
    Blood; 1996 May; 87(10):4376-81. PubMed ID: 8639798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients.
    Rund D; Krichevsky S; Bar-Cohen S; Goldschmidt N; Kedmi M; Malik E; Gural A; Shafran-Tikva S; Ben-Neriah S; Ben-Yehuda D
    Leukemia; 2005 Nov; 19(11):1919-28. PubMed ID: 16167058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results].
    Haase D; Hanf V; Schulz T
    Med Klin (Munich); 2004 Sep; 99(9):506-17. PubMed ID: 15372180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
    Quintás-Cardama A; Daver N; Kim H; Dinardo C; Jabbour E; Kadia T; Borthakur G; Pierce S; Shan J; Cardenas-Turanzas M; Cortes J; Ravandi F; Wierda W; Estrov Z; Faderl S; Wei Y; Kantarjian H; Garcia-Manero G
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):401-10. PubMed ID: 24875590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary myelodysplastic syndromes and leukaemias.
    Levine EG; Bloomfield CD
    Clin Haematol; 1986 Nov; 15(4):1037-80. PubMed ID: 3552347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype.
    Horiike S; Misawa S; Kaneko H; Sasai Y; Kobayashi M; Fujii H; Tanaka S; Yagita M; Abe T; Kashima K; Taniwaki M
    Leukemia; 1999 Aug; 13(8):1235-42. PubMed ID: 10450752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors.
    Takeyama K; Seto M; Uike N; Hamajima N; Ino T; Mikuni C; Kobayashi T; Maruta A; Muto Y; Maseki N; Sakamaki H; Saitoh H; Shimoyama M; Ueda R
    Int J Hematol; 2000 Feb; 71(2):144-52. PubMed ID: 10745624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
    Larson RA; Wang Y; Banerjee M; Wiemels J; Hartford C; Le Beau MM; Smith MT
    Blood; 1999 Jul; 94(2):803-7. PubMed ID: 10397748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer.
    Leonard DG; Travis LB; Addya K; Dores GM; Holowaty EJ; Bergfeldt K; Malkin D; Kohler BA; Lynch CF; Wiklund T; Stovall M; Hall P; Pukkala E; Slater DJ; Felix CA
    Clin Cancer Res; 2002 May; 8(5):973-85. PubMed ID: 12006509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders.
    Rowley JD; Reshmi S; Sobulo O; Musvee T; Anastasi J; Raimondi S; Schneider NR; Barredo JC; Cantu ES; Schlegelberger B; Behm F; Doggett NA; Borrow J; Zeleznik-Le N
    Blood; 1997 Jul; 90(2):535-41. PubMed ID: 9226152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
    Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
    Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication errors in hematological neoplasias: genomic instability in progression of disease is different among different types of leukemia.
    Ohyashiki JH; Ohyashiki K; Aizawa S; Kawakubo K; Shimamoto T; Iwama H; Hayashi S; Toyama K
    Clin Cancer Res; 1996 Sep; 2(9):1583-9. PubMed ID: 9816337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
    Felix CA; Hosler MR; Winick NJ; Masterson M; Wilson AE; Lange BJ
    Blood; 1995 Jun; 85(11):3250-6. PubMed ID: 7756657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
    Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P
    Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
    Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
    Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia.
    Olipitz W; Hopfinger G; Aguiar RC; Gunsilius E; Girschikofsky M; Bodner C; Hiden K; Linkesch W; Hoefler G; Sill H
    Genes Chromosomes Cancer; 2002 Jun; 34(2):243-8. PubMed ID: 11979558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
    Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
    Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases.
    Merlat A; Lai JL; Sterkers Y; Demory JL; Bauters F; Preudhomme C; Fenaux P
    Leukemia; 1999 Feb; 13(2):250-7. PubMed ID: 10025899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.